TumorDiagnostik & Therapie 2002; 23(6): 219-224
DOI: 10.1055/s-2002-36487
Originalarbeit/Original Article
© Georg Thieme Verlag Stuttgart · New York

Gemcitabine-Containing Chemotherapy in the Treatment of Patients with Advanced Soft Tissue Sarcoma

Gemcitabinhaltige Chemotherapie in der Behandlung von Patienten mit fortgeschrittenen WeichteilsarkomenS.  Bauer1 , J.  Hartung1 , T.  Gauler1 , P.  Gocke2 , T.  Trarbach1 , M.  Flasshove1 , M.  R.  Nowrousian1 , P.  Bojko1 , J.  Hense1 , S.  Seeber1 , J.  Schütte1
  • 1Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Essen, Germany
  • 2Zentralinstitut für Röntgendiagnostik, Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Essen, Germany
Further Information

Publication History

Publication Date:
07 January 2003 (online)


Background: To assess the role of gemcitabine (G) or gemcitabine-containing regimens (GCR) in advanced soft tissue sarcoma (STS), we analyzed the response rate and the time-to-progression (TTP) in advanced STS patients (pts) following G/GCR treatment. Patients and Methods: From 8/98 to 12/01, 38 pts were treated with G alone (N = 9), or GCR including docetaxel (N=14); cisplatin (N = 13); or vinorelbine or paclitaxel (N = 2). Histologies included advanced STS in 32 pts and gastrointestinal stromal tumors (GIST) in 6 pts. Thirty-three pts including 27 STS pts had been pre-treated with a median of two prior regimens. Therapy consisted of a median of 3 cycles (range: 1 - 13) of G/GCR at a median G dose/application of 909 mg/m2 infused over 30 min. Results: Among the 32 non-GIST pts, there were 5 partial (15.6 %) and 2 minor (6 %) responses, with a median response duration of 17.8 + (range, 15.5 + - 63 +) weeks. In the group of 27 pre-treated STS pts, 3 partial (11 %) and 2 minor (7 %) responses were observed. With a median follow-up of 26 weeks, the median time-to-progression (TTP) was 18.4 weeks. Progression-free rates at 8, 12, and 24 weeks among pre-treated STS pts. were 73 %, 68 %, and 35 %, respectively. Conclusion: The response and PF rates observed in this analysis are comparable to those previously described for second-line anthracyclines and DTIC. Given the limited number of active cytostatic drugs for STS pts, these data suggest further evaluation of G or G-containing regimens in advanced STS.


Dr. Sebastian Bauer

Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen,
Westdeutsches Tumorzentrum

Hufelandstr. 55

45122 Essen


Phone: +49-201-723-2024

Fax: +49-201-723-5925

Email: [email protected]